Sihuan Pharmaceutical Holdings Group (FRA:TEL1) Total Stockholders Equity : €566.2 Mil (As of Jun. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Total Stockholders Equity?

Sihuan Pharmaceutical Holdings Group's Total Stockholders Equity for the quarter that ended in Jun. 2024 was €566.2 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sihuan Pharmaceutical Holdings Group's Book Value per Share for the quarter that ended in Jun. 2024 was €0.06. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sihuan Pharmaceutical Holdings Group's Debt-to-Equity for the quarter that ended in Jun. 2024 was 0.26.

Sihuan Pharmaceutical Holdings Group Total Stockholders Equity Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Total Stockholders Equity Chart

Sihuan Pharmaceutical Holdings Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

1,232.73

1,155.24

1,151.06

641.41

569.21

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Stockholders Equity	Get a 7-Day Free Trial															1,026.00	641.41	567.86	569.21	566.16

Sihuan Pharmaceutical Holdings Group (FRA:TEL1) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sihuan Pharmaceutical Holdings Group's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(566.158	-	0)	/	9320
	=	0.06

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sihuan Pharmaceutical Holdings Group's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(30.973	+	113.445)	/	566.158
	=	0.26

Sihuan Pharmaceutical Holdings Group Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sihuan Pharmaceutical Holdings Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (FRA:TEL1) » Definitions » Total Stockholders Equity

Traded in Other Exchanges

SHPHF:USA 00460:Hong Kong

Address

Zhubang 2000, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025

Website

https://www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segments; and the generic medicine segment which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.

Sihuan Pharmaceutical Holdings Group Headlines

No Headlines